Home › RLT targets by cancer › Testicular Cancer
Radioligand therapy · Testicular Cancer

Radioligand Therapy Targets in Testicular Cancer

Updated 2026-11 · Ranked from Human Protein Atlas, Open Targets, ClinicalTrials.gov and PubMed evidence

We screened every cell-surface protein with tumor immunohistochemistry data in testicular cancer (including testicular germ cell tumors). 4,122 show detectable protein staining. Established and emerging radioligand targets expressed in testicular cancer include HER3 (ERBB3), STEAP2, c-MET (MET) and KIT. Below, we rank every candidate by tumor expression, internalization and clinical maturity.

Need a shortlist for your own testicular cancer program? Rank every candidate against your isotope, organ-dose limits and novelty bar.

Rank testicular cancer targets free

Established and emerging radioligand targets in testicular cancer

Targets already pursued with radioligands or other targeted modalities that show protein expression in testicular cancer:

TargetIHC in testicular cancer% positiveInternalizes
HER3 (ERBB3)High (0.87)100%yes
STEAP2High (0.64)100%—
c-MET (MET)High (0.52)100%yes
KITMedium (0.39)50%no
B7-H3 (CD276)Medium (0.33)80%—
TMEFF2Medium (0.33)80%—
EPCAMLow (0.17)40%—
Nectin-4 (NECTIN4)Low (0.15)36%no
FAPLow (0.14)42%yes
Claudin 18.2 (CLDN18)Low (0.12)27%uncertain
SSTR2Low (0.11)25%yes
HER2 (ERBB2)Low (0.07)22%yes
CD38Low (0.07)20%—
ITGB6Low (0.07)20%—
DLK1Low (0.06)9%—
Mesothelin (MSLN)Low (0.06)8%yes

Top cell-surface targets for testicular cancer radioligand therapy

A data-driven screen of every protein annotated as cell-surface. It deliberately surfaces novel, unvalidated candidates, so confirm localization and expression before prioritizing any of them.

#TargetIHC in testicular cancer% positiveInternalizesClinical stage
1HER3 (ERBB3)
erb-b2 receptor tyrosine kinase 3
High (0.87)100%yesFDA-Approved
2IGF1R
insulin like growth factor 1 receptor
High (0.85)100%yesFDA-Approved
3EPHB2
EPH receptor B2
High (0.92)100%uncertainFDA-Approved
4NR3C2
nuclear receptor subfamily 3 group C member 2
High (0.89)100%uncertainFDA-Approved
5PTPN13
protein tyrosine phosphatase non-receptor type 13
High (0.97)100%yesDiscovery
6GPR139
G protein-coupled receptor 139
High (1.00)100%yesDiscovery
7AMFR
autocrine motility factor receptor
High (0.97)100%yesDiscovery
8S1PR1
sphingosine-1-phosphate receptor 1
Medium (0.48)100%yesFDA-Approved
9c-MET (MET)
MET proto-oncogene, receptor tyrosine kinase
High (0.52)100%yesFDA-Approved
10ABCC8
ATP binding cassette subfamily C member 8
High (0.97)100%—FDA-Approved
11NOTCH1
notch receptor 1
High (0.70)100%yesClinical
12IL1R2
interleukin 1 receptor type 2
High (0.69)100%yesDiscovery
13FZD6
frizzled class receptor 6
High (0.87)100%yesDiscovery
14M6PR
mannose-6-phosphate receptor, cation dependent
High (0.87)100%yesDiscovery
15FZD3
frizzled class receptor 3
High (0.85)100%yesDiscovery
16AGTRAP
angiotensin II receptor associated protein
High (0.83)100%yesDiscovery
17NOTCH2
notch receptor 2
High (0.64)100%yesClinical
18ADRM1
ADRM1 26S proteasome ubiquitin receptor
High (0.86)100%uncertainFDA-Approved
19EPHA3
EPH receptor A3
High (0.52)100%yesFDA-Approved
20FGFR1
fibroblast growth factor receptor 1
Medium (0.47)100%yesFDA-Approved
21EEF2
eukaryotic translation elongation factor 2
High (0.97)100%—FDA-Approved
22CHRNA7
cholinergic receptor nicotinic alpha 7 subunit
High (0.61)100%yesClinical
23CSPG4
chondroitin sulfate proteoglycan 4
High (1.00)100%—Discovery
24TNFRSF12A
TNF receptor superfamily member 12A
High (0.92)100%uncertainClinical
25GPER1
G protein-coupled estrogen receptor 1
High (0.78)92%yesDiscovery

Internalizing receptors in testicular cancer

Targets expressed in testicular cancer that the literature reports internalize after ligand binding. Internalization traps the radionuclide inside the tumor cell, which matters most for β-emitters like 177Lu and for α-emitters like 225Ac:

HER3 (ERBB3) · IGF1R · PTPN13 · GPR139 · AMFR · S1PR1 · c-MET (MET) · NOTCH1 · IL1R2 · FZD6 · M6PR · FZD3

Testicular Cancer targets already in clinical development

Targets with a clinical-stage drug program (any modality) that are also expressed in testicular cancer. Clinical precedent lowers development risk but usually means more competition:

HER3 (ERBB3) · IGF1R · EPHB2 · NR3C2 · S1PR1 · c-MET (MET) · ABCC8 · NOTCH1 · NOTCH2 · ADRM1 · EPHA3 · FGFR1

How these testicular cancer targets are ranked

Candidates are limited to proteins annotated as cell-surface (UniProt via Open Targets), because a radioligand has to reach its target from circulation. They are ranked by Nuclens' radiopharmaceutical pre-screen: immunohistochemistry staining and patient-sample positivity in testicular cancer, literature evidence of internalization and shedding, clinical maturity, and cancer association. It is a first-pass triage, not a substitute for wet-lab validation or dosimetry. For the full framework, see what makes a good radioligand therapy target and emerging radioligand targets beyond PSMA.

Rank testicular cancer targets against your own criteria: isotope, organ limits, novelty.

Run a free testicular cancer analysis

Radioligand therapy targets in other cancers

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Shortlist testicular cancer targets for your program · 5 free analyses, no card Rank testicular cancer targets free